$MNOV cup with handle $3.48 called 9/2/14 W
Post# of 63700
Posted On: 12/13/2015 2:03:32 PM
$MNOV cup with handle
$3.48
called 9/2/14
Website
Shares Outstanding: 25.96M
Float: 26.24M
% Held by Insiders: 22.50%
% Held by Institutions: 8.50%
Shares Short (as of Nov 30, 2015): 333.86K
Short Ratio (as of Nov 30, 2015)3: 9.56
Short % of Float (as of Nov 30, 2015): 1.53%
Shares Short (prior month): 403.50K
Headlines
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
$3.48
called 9/2/14
Website
Shares Outstanding: 25.96M
Float: 26.24M
% Held by Insiders: 22.50%
% Held by Institutions: 8.50%
Shares Short (as of Nov 30, 2015): 333.86K
Short Ratio (as of Nov 30, 2015)3: 9.56
Short % of Float (as of Nov 30, 2015): 1.53%
Shares Short (prior month): 403.50K
Headlines
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
(0)
(0)Scroll down for more posts ▼